Shaun Marcus
Keine laufenden Positionen mehr
Profil
Shaun Marcus served as Director at Aspireo Pharmaceuticals Ltd.
from 2010 to 2015.
He was also Chief Financial Officer at Friction Control Solutions, Inc., Peptor Ltd, and PolyPid Ltd.
In 2013, he worked as a Manager at DeveloGen AG.
Marcus completed his undergraduate degree at Tel-Aviv University.
Ehemalige bekannte Positionen von Shaun Marcus
Unternehmen | Position | Ende |
---|---|---|
Aspireo Pharmaceuticals Ltd.
Aspireo Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Aspireo Pharmaceuticals Ltd. operates as a biopharmaceutical company. It focuses on the development of of a novel somatostatin analog for the treatment of diseases resulting from hormone-active tumors, such as acromegaly, neuroendocrine and gastroenteropancreatic tumors, Cushing ’s disease and diabetic retinopathy. The company’s sole development compound is Somatoprim (DG3173), a novel and proprietary somatostatin analog that is based on a novel amino acid composition and a unique backbone cyclization technology used for stabilization of the peptide. Aspireo Pharmaceuticals was founded in 2010 and is headquartered in Tel Aviv, Israel. | Finanzdirektor/CFO | - |
POLYPID LTD. | Finanzdirektor/CFO | - |
Friction Control Solutions, Inc.
Friction Control Solutions, Inc. Industrial SpecialtiesProcess Industries Friction Control Solutions, Inc. develops and manufactures polymer based devices. It provides significant added value services to the automotive, aerospace and energy industries. The company was founded by Amir Weisberg, Boris Shamshidov and Alexander Ignatovsky in 2003 and headquartered in Farmington Hills, MI. | Finanzdirektor/CFO | - |
Peptor Ltd | Finanzdirektor/CFO | - |
DeveloGen AG
DeveloGen AG Pharmaceuticals: MajorHealth Technology DeveloGen AG is a biopharmaceutical company engaged in the discovery and development of novel therapeutics for the treatment of metabolic and endocrine disorders with a particular focus on diabetes. DeveloGen develops highly innovative approaches for the treatment of diabetes and obesity targeting key pathophysiological mechanisms such as insulin resistance and loss of insulin-producing beta cells. DeveloGen's product pipeline includes two programs at advanced stages of lead optimization, a small molecule inhibitor program based on a novel and proprietary target to address insulin resistance (type 2 diabetes). A growth factor targeting beta cell regeneration (type 1 and type 2 diabetes). DeveloGen is based in Goettingen, Germany. | Corporate Officer/Principal | - |
Ausbildung von Shaun Marcus
Tel-Aviv University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
POLYPID LTD. | Health Technology |
Private Unternehmen | 4 |
---|---|
DeveloGen AG
DeveloGen AG Pharmaceuticals: MajorHealth Technology DeveloGen AG is a biopharmaceutical company engaged in the discovery and development of novel therapeutics for the treatment of metabolic and endocrine disorders with a particular focus on diabetes. DeveloGen develops highly innovative approaches for the treatment of diabetes and obesity targeting key pathophysiological mechanisms such as insulin resistance and loss of insulin-producing beta cells. DeveloGen's product pipeline includes two programs at advanced stages of lead optimization, a small molecule inhibitor program based on a novel and proprietary target to address insulin resistance (type 2 diabetes). A growth factor targeting beta cell regeneration (type 1 and type 2 diabetes). DeveloGen is based in Goettingen, Germany. | Health Technology |
Friction Control Solutions, Inc.
Friction Control Solutions, Inc. Industrial SpecialtiesProcess Industries Friction Control Solutions, Inc. develops and manufactures polymer based devices. It provides significant added value services to the automotive, aerospace and energy industries. The company was founded by Amir Weisberg, Boris Shamshidov and Alexander Ignatovsky in 2003 and headquartered in Farmington Hills, MI. | Process Industries |
Peptor Ltd | Health Technology |
Aspireo Pharmaceuticals Ltd.
Aspireo Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Aspireo Pharmaceuticals Ltd. operates as a biopharmaceutical company. It focuses on the development of of a novel somatostatin analog for the treatment of diseases resulting from hormone-active tumors, such as acromegaly, neuroendocrine and gastroenteropancreatic tumors, Cushing ’s disease and diabetic retinopathy. The company’s sole development compound is Somatoprim (DG3173), a novel and proprietary somatostatin analog that is based on a novel amino acid composition and a unique backbone cyclization technology used for stabilization of the peptide. Aspireo Pharmaceuticals was founded in 2010 and is headquartered in Tel Aviv, Israel. | Health Technology |